These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25445025)

  • 1. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
    Cassaday RD; Storer BE; Sorror ML; Sandmaier BM; Guthrie KA; Maloney DG; Rajendran JG; Pagel JM; Flowers ME; Green DJ; Rezvani AR; Storb RF; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):281-7. PubMed ID: 25445025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy in allogeneic nonmyeloablative conditioning for B cell lymphoma: should we use it more often?
    Khouri IF
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):199-200. PubMed ID: 25528389
    [No Abstract]   [Full Text] [Related]  

  • 3. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
    Gopal AK; Guthrie KA; Rajendran J; Pagel JM; Oliveira G; Maloney DG; Matesan MC; Storb RF; Press OW
    Blood; 2011 Jul; 118(4):1132-9. PubMed ID: 21508413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-Up of
    Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
    Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
    Sauter CS; Barker JN; Lechner L; Zheng J; Devlin SM; Papadopoulos EB; Perales MA; Jakubowski AA; Goldberg JD; Koehne G; Ceberio I; Giralt S; Zelenetz AD; Moskowitz CH; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):354-60. PubMed ID: 24315843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
    Khouri IF; Saliba RM; Giralt SA; Lee MS; Okoroji GJ; Hagemeister FB; Korbling M; Younes A; Ippoliti C; Gajewski JL; McLaughlin P; Anderlini P; Donato ML; Cabanillas FF; Champlin RE
    Blood; 2001 Dec; 98(13):3595-9. PubMed ID: 11739162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
    Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
    JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
    Bethge WA; Lange T; Meisner C; von Harsdorf S; Bornhaeuser M; Federmann B; Stadler M; Uharek L; Stelljes M; Knop S; Wulf G; Trenschel R; Vucinic V; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
    Blood; 2010 Sep; 116(10):1795-802. PubMed ID: 20530284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.
    Khouri IF; Saliba RM; Erwin WD; Samuels BI; Korbling M; Medeiros LJ; Valverde R; Alousi AM; Anderlini P; Bashir Q; Ciurea S; Gulbis AM; de Lima M; Hosing C; Kebriaei P; Popat UR; Fowler N; Neelapu SS; Samaniego F; Champlin RE; Macapinlac HA
    Blood; 2012 Jun; 119(26):6373-8. PubMed ID: 22586182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
    Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
    Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
    Bethge WA; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
    Bone Marrow Transplant; 2012 Nov; 47(11):1397-402. PubMed ID: 22504934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
    Brammer JE; Stentz A; Gajewski J; Curtin P; Hayes-Lattin B; Kovacsovics T; Leis JF; Meyers G; Nemecek E; Subbiah N; Frires R; Palmbach G; Avraham GP; Slater S; Maziarz RT
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.